2026-01-19 - Analysis Report
**English Report**

### Company Overview
REGN - 바이오 의료 기기 및 진단 장비 글로벌 리더

### Return Rate Analysis

* Cumulative Return of Review Stock: -9.33%
* Cumulative Return of Comparison Stock (S&P 500, VOO): 82.54%
* Divergence (max: N/A, min: N/A, current: N/A, relative divergence: N/A)
* The current cumulative return of REGN is -9.33% compared to S&P 500's 82.54%.

### Alpha, Beta Analysis
| Year | CAGR | MDD  | Alpha | Beta | Cap(B) |
|------------|------|------|-------|------|-------|
| 2016-2018  | 0.0% | 12.8% | 0.0% | 1.2 | 39.6B |
| 2017-2019  | 11.0% | 12.8% | 2.0% | 1.0 | 39.8B |
| 2018-2020  | 10.0% | 15.0% | -11.0% | 0.7 | 51.2B |
| 2019-2021  | 29.0% | 15.1% | -8.0% | 0.6 | 66.9B |
| 2020-2022  | 20.0% | 15.4% | 10.0% | 0.6 | 76.5B |
| 2021-2023  | 19.0% | 15.4% | 3.0% | 0.6 | 93.1B |
| 2022-2024  | -29.0% | 32.8% | -56.0% | 0.6 | 75.5B |
| 2023-2025  | -38.0% | 44.2% | -87.0% | 0.6 | 81.8B |

### Recent Stock Price Fluctuations

* Close: $733.04
* Last-Market: $733.04
* Price Change: -1.2%
* 5-day SMA: $751.20
* 20-day SMA: $772.91
* 60-day SMA: $721.13

### RSI, PPO Index Indicators

* Market Risk Indicator (MRI): 0.80
* RSI: 33.66
* PPO: -1.10
* Hybrid Signal: Sell (Shares 86%)
* Risk Level: Medium (MRI 0.80)
* Recent (20 days) relative divergence change: 0.0
* 7-day Rank change: 0
* 7-day Dynamic Expected Return change: 0.0

### Recent News & Significant Events

* [2026-01-18] Regeneron Pharmaceuticals, Inc. $REGN Stock Holdings Raised by Lmcg Investments LLC - MarketBeat
* [2026-01-18] Does Regeneron (REGN) Prioritizing In‑House R&D Over Deals Recast Its Long‑Term Risk‑Reward Profile? - simplywall.st
* [2026-01-06] REGN vs. ILMN: Which Stock Should Value Investors Buy Now? - Yahoo Finance
* [2026-01-02] Regeneron Pharmaceuticals to Announce Fourth Quarter and Full Year 2025 Financial Results on January 30, 2026 - Quiver Quantitative
* [2026-01-18] Howland Capital Management LLC Raises Stock Holdings in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
* [2026-01-02] REGN Soars 41% in Six Months: Is There More Upside Potential in 2026? - Zacks Investment Research

### Analyst Opinions

* Analyst Consensus:
	+ Key: Buy
	+ Mean (1=StrongBuy~5=Sell): 1.69 (~Buy)
	+ Opinions: 26
	+ Target Price (avg/high/low): 826.04 / 1057.00 / 630.00

### Recent Earnings Analysis
| Date | EPS | Revenue |
|---|---:|---:|
| 2025-10-28 | 14.09 | 3.75 B$ |
| 2025-08-01 | 13.24 | 3.68 B$ |
| 2025-04-29 | 7.58 | 3.03 B$ |
| 2024-10-31 | 12.4 | 3.72 B$ |

### Financial Information
#### Revenue and Profitability
| Quarter | Revenue | Profit Margin |
|---------|----------|---------------|
| 2025-09-30 | $3.75B | 86.11% |
| 2025-06-30 | $3.68B | 85.58% |
| 2025-03-31 | $3.03B | 84.67% |
| 2024-12-31 | $3.79B | 85.08% |
| 2024-09-30 | $3.72B | 86.80% |

#### Capital and Profitability
| Quarter | Equity | ROE |
|---------|---------|-----|
| 2025-09-30 | $30.96B | 4.72% |
| 2025-06-30 | $29.94B | 4.65% |
| 2025-03-31 | $29.39B | 2.75% |
| 2024-12-31 | $29.35B | 3.13% |
| 2024-09-30 | $29.33B | 4.57% |

### Comprehensive Analysis

REGN's cumulative return is -9.33% compared to S&P 500's 82.54%. The stock's recent price fluctuations show a decline, but the 20-day SMA is still at $772.91. The RSI and PPO indicators suggest a sell signal, and the market risk indicator is at 0.80, indicating a medium risk level. Analyst opinions are generally positive, with a mean opinion score of 1.69 (~Buy). The stock's revenue and profitability have been increasing, but the profit margin has been fluctuating. Overall, the comprehensive analysis suggests a mixed view of the stock.

**Disclaimer:** This report is for informational purposes only and does not constitute financial advice. Investment involves risk.